Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc
The United States Court of Appeals for the Federal Circuit affirmed a district court ruling that Mylan Pharmaceuticals did not infringe Actelion Pharmaceuticals' patents for a stable epoprostenol drug formulation. The court held that the patent claim term requiring a pH of thirteen or higher refers to measurements taken at standard temperature, and that Actelion was barred from asserting infringement by equivalence.